# Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

> **NCT01727336** · PHASE2 · TERMINATED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 160 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Dalantercept and axitinib
- **DRUG:** Placebo and axitinib

## Key facts

- **NCT ID:** NCT01727336
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2017-06
- **Final completion:** 2017-11
- **Target enrollment:** 160 (ACTUAL)
- **Why stopped:** The study was terminated by the sponsor following unblinding of the Progression Free Survival endpoint.
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01727336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01727336, "Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01727336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*